Interrelation of blood lipid spectrum, level of systemic inflammation and mass of body in patients with coronary heart disease in combination with nonalcoholic fatty liver disease and their dynamics in terms of secondary prevention

• Main Authors: Kuryata O.V., Grechanyk M.M.
• Format: Article
• Language: English
• Published: SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine" 2014-11-01
• Series: Medičnì Perspektivi
• Subjects: ischemic heart disease; nonalcoholic fatty liver disease; blood lipid spectrum; statins
• Online Access: http://medpers.dsma.dp.ua/issues/2014/N4/103-111.pdf

The article analyzes the blood lipid spectrum, level of systemic inflammation and their dynamics depending on body mass index in patients with coronary heart disease (CHD) in combination with nonalcoholic fatty liver disease (NAFLD) under the of influence statin therapy. 20 men (mean age 56,4±1,44 years) with CHD and NAFLD were examined. Levels of triglycerides (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP) were studied. 2 groups of patients according to BMI were distinguished: group 1 consisted of 9 (45%) patients who are overweight (BMI 25 to 30 kg/m2), group 2-8 (40%) with first degree of obesity (BMI 30 to 35). It was at found that at the initial state BMI increase at the range of 25-35 kg/m2 was not associated with a significant difference in the lipid spectrum, on the other hand on the background of treatment with pitavastatin in the dose of 2 mg for 8 weeks in patients with BMI of 25-30 kg/m2 more intensive reduction of TG (56.6%), LDL-C (31,8%), total cholesterol (22%), CRP (29.8%) and increased HDL-C (14,7%) was registered in contrast to the patients with BMI 30-35 kg/m2 – 33,7%, 22,8%, 8,8%, 10,1%, 11,9% respectively. Thus, in patients with CHD and NAFLD, pitavastatin in the dose of 2 mg has a moderate lipid-lowering effect, causes no significant increase in liver transaminases, which required dose adjustment or discontinuation of the drug.